A germline JAK2 SNP is associated with predisposition to the development of JAK2V617F-positive myeloproliferative neoplasms
Nature Genetics2009Vol. 41(4), pp. 455–459
Citations Over TimeTop 1% of 2009 papers
Outi Kilpivaara, Semanti Mukherjee, Alison M. Schram, Martha Wadleigh, Ann Mullally, Benjamin L. Ebert, Adam J. Bass, Sachie Marubayashi, Adriana Heguy, Guillermo Garcia‐Manero, Hagop M. Kantarjian, Kenneth Offit, Richard M. Stone, D. Gary Gilliland, Robert J. Klein, Ross L. Levine
Related Papers
- → Megakaryocytic Morphology and Clinical Parameters in Essential Thrombocythemia, Polycythemia Vera, and Primary Myelofibrosis With and Without JAK2 V617F(2014)21 cited
- → Non-driver mutations in myeloproliferative neoplasm-associated myelofibrosis(2017)21 cited
- → Patients with post polycythemia vera myelofibrosis might experience increased thrombotic risk in comparison to primary and post essential thrombocythemia myelofibrosis(2022)17 cited
- The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.(2009)
- → Elevated Peripheral Blood (4-9%) and Bone Marrow Blasts (5-9%) are Associated with Poor Prognosis in Patients with Primary Myelofibrosis as Well as Post-Essential Thrombocythemia and Post-Polycythemia Vera Myelofibrosis(2017)1 cited